JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
This is used to treat central diabetes insipidus and bedwetting
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
India has taken the lead in recognising NAFLD as a major non-communicable disease
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Subscribe To Our Newsletter & Stay Updated